- Home
- GYRE vs CMP Comparison
GYRE vs CMP Comparison
Compare GYRE & CMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- CMP
- Stock Information
- Founded
- GYRE 2002
- CMP 1993
- Country
- GYRE United States
- CMP United States
- Employees
- GYRE N/A
- CMP N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- CMP Other Metals and Minerals
- Sector
- GYRE Health Care
- CMP Basic Materials
- Exchange
- GYRE Nasdaq
- CMP Nasdaq
- Market Cap
- GYRE 897.1M
- CMP 836.2M
- IPO Year
- GYRE N/A
- CMP 2003
- Fundamental
- Price
- GYRE $7.57
- CMP $21.47
- Analyst Decision
- GYRE
- CMP Buy
- Analyst Count
- GYRE 0
- CMP 3
- Target Price
- GYRE N/A
- CMP $19.00
- AVG Volume (30 Days)
- GYRE 159.6K
- CMP 689.9K
- Earning Date
- GYRE 08-12-2025
- CMP 09-16-2025
- Dividend Yield
- GYRE N/A
- CMP N/A
- EPS Growth
- GYRE N/A
- CMP N/A
- EPS
- GYRE 0.02
- CMP N/A
- Revenue
- GYRE $100,643,000.00
- CMP $1,213,500,000.00
- Revenue This Year
- GYRE $21.04
- CMP $11.60
- Revenue Next Year
- GYRE $89.64
- CMP $2.33
- P/E Ratio
- GYRE $95.15
- CMP N/A
- Revenue Growth
- GYRE N/A
- CMP 5.81
- 52 Week Low
- GYRE $6.11
- CMP $7.51
- 52 Week High
- GYRE $19.00
- CMP $22.69
- Technical
- Relative Strength Index (RSI)
- GYRE 47.42
- CMP 57.24
- Support Level
- GYRE $7.09
- CMP $20.31
- Resistance Level
- GYRE $7.63
- CMP $21.72
- Average True Range (ATR)
- GYRE 0.40
- CMP 0.71
- MACD
- GYRE 0.03
- CMP -0.18
- Stochastic Oscillator
- GYRE 42.74
- CMP 48.78
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.